Bestaande gebruiker? Log in
Abonneren
Home
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Analisten vandaag
Meest aanbevolen aandelen
Minst aanbevolen aandelen
Aandelen met grootste potentieel
Insider trading
Insiders vandaag
Meest gekochte aandelen
Meest verkochte aandelen
Mijn Trivano
Mijn Trivano
Mijn selecties
Mijn nieuwsbrieven
Abonneren
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Insider trading
Mijn Trivano
Registreren / inloggen
Beurs vandaag
Amerika
Biomarin Pharmaceutical Inc.
Nieuws
Biomarin Pharmaceutical Inc.
BMRN
NAS
: BMRN
| ISIN: US09061G1013
7/05/2024
82,58 USD
(+0,58%)
(+0,58%)
7/05/2024
Aandeel volgen
Aandeel gevolgd
Samenvatting
Nieuws
Insiders
Technische analyse
TA
Toon enkel gratis nieuws
4 mei 2024 ·
New Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting
· Persbericht
24 april 2024 ·
BioMarin Reports Record Financial Results for the First Quarter 2024
· Persbericht
10 april 2024 ·
BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET
· Persbericht
12 maart 2024 ·
New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
· Persbericht
7 maart 2024 ·
BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer
· Persbericht
1 maart 2024 ·
BioMarin Scheduled to Participate in March Investor Conferences
· Persbericht
22 februari 2024 ·
BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024
· Persbericht
8 februari 2024 ·
BioMarin to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Thursday, February 22, 2024, at 4:30pm ET
· Persbericht
6 februari 2024 ·
BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) Data Highlighting Long-Term Durability at 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress
· Persbericht
3 januari 2024 ·
BioMarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 10:30 am PT / 1:30 pm ET, in San Francisco, CA
· Persbericht
20 december 2023 ·
BioMarin Announces Governance Enhancements and Value Creation Initiatives
· Persbericht
1 november 2023 ·
BioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over Year
· Persbericht
1 november 2023 ·
BioMarin Announces Retirement of Jean-Jacques Bienaimé; Appoints Alexander Hardy President and Chief Executive Officer
· Persbericht
20 oktober 2023 ·
U.S. Food and Drug Administration Approves BioMarin's VOXZOGO® (vosoritide) for Children Under 5 Years with Achondroplasia
· Persbericht
17 oktober 2023 ·
BioMarin to Host Third-Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, November 1, at 4:30pm ET
· Persbericht
21 september 2023 ·
BioMarin to Present Data Showing Long-Term Benefit of VOXZOGO® (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology (ESPE) Meeting
· Persbericht
15 september 2023 ·
BioMarin Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO® (vosoritide) to Treat Children Aged 4 Months and Older with Achondroplasia
· Persbericht
11 september 2023 ·
BioMarin to Present Innovative Pipeline at R&D Day on September 12th in New York
· Persbericht
6 september 2023 ·
BioMarin to Present Pipeline at Upcoming R&D Day on Tuesday, September 12th
· Persbericht
5 september 2023 ·
BioMarin to Participate in Three Upcoming Investor Conferences
· Persbericht
Aandeel volgen
Aandeel gevolgd
Mijn selecties
Voorbeeldselectie
Je selectie is nog leeg.
Voeg nu effecten toe